Shionogi USA: ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S-217622

FDA has cleared the IND for S-217622, a once-daily investigational oral antiviral therapy, enabling the global phase 3 trial to proceed as part of the ACTIV-2 program for COVID-19 This NIH-supported

Related Keywords

California ,United States ,San Diego ,Osaka ,Japan ,Los Angeles ,San Francisco ,America ,Japanese ,Annie Luetkemeyer ,Weber Shandwick ,Davey Smith ,Josephj Eron ,Isao Teshirogi ,Judith Currier ,Jenna Conley ,Elizabeth Adelanwa ,Erics Daar ,David Alain Wohl ,University Of California ,Shionogi Co Ltd ,National Institutes Of Health ,National Institute Of Allergy ,Clinical Trials Group ,Drug Administration ,University Of North Carolina ,Lundquist Institute At ,Hokkaido University ,Shionogi Inc ,Corporate Communications ,Trials Group ,National Institute ,Infectious Diseases ,National Institutes ,Investigational New Drug ,Emergency Use Authorizations ,South America ,North America ,North Carolina ,Lundquist Institute ,Protease Inhibitor ,Shionogi ,Octg ,Nnounce ,Progress ,Lobal ,Hase ,Trial ,Novel ,Covid ,Mural ,Antiviral ,Agent ,17622 ,